We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals
AMPH

95 hedge funds and large institutions have $172M invested in Amphastar Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 42 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 22

0% more funds holding

Funds holding: 95 → 95 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

19% less capital invested

Capital invested by funds: $213M → $172M (-$41.2M)

Holders
95
Holders Change
–
Holders Change %
0%
% of All Funds
2.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
42
Reduced
22
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.55M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.23M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.99M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.61M
5
SGAM
Smith Group Asset Management
Texas
+$1.29M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$14.6M
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.2M
3
TC
TFS Capital
Pennsylvania
-$2.16M
4
JP Morgan Chase
JP Morgan Chase
New York
-$1.68M
5
JG
Jefferies Group
New York
-$1.48M

AMPH Hedge Fund Activity: Q1 2016 in Review

95 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2016, worth a combined $172M — down 19% from $213M a quarter earlier.

Fund positioning in AMPH was balanced in Q1 2016: 10 funds opened new positions, 10 closed out, 42 added to existing stakes and 22 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $4.55M. The largest seller was Broadfin Capital, exiting entirely with an estimated $14.6M sold.

  • 95 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $172M of Amphastar Pharmaceuticals stock for Q1 2016, down 19% quarter-over-quarter.
  • 10 funds opened new Amphastar Pharmaceuticals positions in Q1 2016 and 10 closed out, a net change of 0 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q1 2016 was Fidelity Investments, an estimated $4.55M added.
  • The largest Amphastar Pharmaceuticals seller in Q1 2016 was Broadfin Capital, an estimated $14.6M sold.

Based on aggregated 13F filings for Q1 2016.